This study tests a PARP inhibitor; the registry reports that it was terminated after five people had enrolled.
The registry lists NCT06931626 as terminated, last updated 2026-11-17. Five participants were enrolled. The sponsor's stated reason: "The decision about study closure has not been based on safety profile or clinical data of NMS-03305293 but due to a strategic decision driven by upcoming changes in the treatment landscape." Interventions: NMS-03305293, Temozolomide. Primary measures include Number of Participants with Adverse Events (AEs). No results are posted in the registry; this does not exclude separate publications.
The full inclusion and exclusion criteria are on the registry record. Read 2026-11-19. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares NMS-03305293, PARP.
Shares NMS-03305293, PARP.
Shares NMS-03305293, PARP.
Shares PARP, Small-cell lung cancer.
Shares PARP, Small-cell lung cancer.
Shares PARP, Small-cell lung cancer.
Shares PARP, Small-cell lung cancer.
Shares PARP, Small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/